Assembly Biosciences announced a $30.1 million capital infusion from Gilead Sciences, comprising a $20.1 million equity investment and $10 million in accelerated funding. This strategic financial boost is expected to extend Assembly Bio's cash runway to mid-2026.
The equity investment increases Gilead's ownership stake in Assembly Bio to 29.9% of outstanding common stock. This deepened collaboration provides substantial financial backing for Assembly Bio's ongoing clinical development programs.
The accelerated funding specifically supports the pipeline, including an amendment to accelerate the clinical development of Assembly Bio’s novel small molecule hepatitis delta virus candidate, ABI-6250. This investment underscores the strategic alignment between the two companies and their commitment to advancing antiviral therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.